Adagene Completes Phase 2 Enrollment for Muzastotug Plus Pembrolizumab in MSS Colorectal Cancer

Coverage, in order

1. 2d ago
   
   OncoDaily obscure study randomized trial

   Adagene Completes Phase 2 Enrollment for Muzastotug Plus Pembrolizumab in MSS Colorectal Cancer

   For patients with microsatellite-stable colorectal cancer (MSS CRC), immunotherapy has long remained a difficult challenge. While immune checkpoint inhibitors have transformed treatment for certain colorectal cancers, the majority of patients

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.